Compare Gold Fields Limited (GFI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs TG Therapeutics Inc — how do they compare? Gold Fields Limited trades at $36.82 (market cap $31.87B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Gold Fields Limited is far larger — about 3.9× TG Therapeutics Inc's market cap, and Gold Fields Limited pays a 6% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gold Fields Limited for 49 Days and TG Therapeutics Inc for 16 Days on average.
| GFI | TGTX | |
|---|---|---|
Market Cap | $31.87B | $8.16B |
Volume | 4,169,651 | 1,735,121 |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $59.06 |
52-Week Low | $31.25 | $26.94 |
Typical Hold Time | 49 Days | 16 Days |
Enterprise Value | $32.47B | $8.37B |
Dividend Yield | 6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $35.86, up 2.31% today, amid a bearish technical signal but strong fundamentals. Revenue surged to $8.75B in 2025 with a net income margin of 38.66%, while valuation ratios like a P/E of 7.3 and EV/EBITDA of 4.64 suggest undervaluation. Recent news centers on a rejected $27B bid for Northern Star, causing volatility, but operational performance remains robust with record cash flow.
The outlook is mixed: analyst consensus is a Buy with a $52.75 price target, but technicals are bearish and earnings misses pose near-term risks. Upside hinges on execution of growth projects and gold price stability, while acquisition-related uncertainty and debt levels warrant caution for investors.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
